Hyundai Pharm (004310) - Net Assets
Based on the latest financial reports, Hyundai Pharm (004310) has net assets worth ₩77.99 Billion KRW (≈ $52.85 Million USD) as of May 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩163.39 Billion ≈ $110.73 Million USD) and total liabilities (₩85.40 Billion ≈ $57.87 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Hyundai Pharm liquidity resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩77.99 Billion |
| % of Total Assets | 47.73% |
| Annual Growth Rate | -1.11% |
| 5-Year Change | -12.28% |
| 10-Year Change | -21.87% |
| Growth Volatility | 7.43 |
Hyundai Pharm - Net Assets Trend (2010–2024)
This chart illustrates how Hyundai Pharm's net assets have evolved over time, based on quarterly financial data. Also explore Hyundai Pharm asset portfolio for the complete picture of this company's asset base.
Annual Net Assets for Hyundai Pharm (2010–2024)
The table below shows the annual net assets of Hyundai Pharm from 2010 to 2024. For live valuation and market cap data, see 004310 market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2024-11-30 | ₩79.07 Billion ≈ $53.59 Million |
-6.60% |
| 2023-11-30 | ₩84.66 Billion ≈ $57.37 Million |
-2.19% |
| 2022-11-30 | ₩86.56 Billion ≈ $58.66 Million |
-0.05% |
| 2021-11-30 | ₩86.60 Billion ≈ $58.69 Million |
-3.93% |
| 2020-11-30 | ₩90.14 Billion ≈ $61.09 Million |
+2.92% |
| 2019-11-30 | ₩87.58 Billion ≈ $59.35 Million |
-18.15% |
| 2018-11-30 | ₩107.00 Billion ≈ $72.52 Million |
+9.08% |
| 2017-11-30 | ₩98.10 Billion ≈ $66.48 Million |
-1.98% |
| 2016-11-30 | ₩100.08 Billion ≈ $67.82 Million |
-1.12% |
| 2013-11-30 | ₩101.21 Billion ≈ $68.59 Million |
+1.53% |
| 2012-11-30 | ₩99.69 Billion ≈ $67.56 Million |
-4.44% |
| 2011-11-30 | ₩104.32 Billion ≈ $70.69 Million |
+12.77% |
| 2010-11-30 | ₩92.50 Billion ≈ $62.69 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Hyundai Pharm's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 26.8% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (November 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩50.10 Billion | 63.36% |
| Other Components | ₩28.97 Billion | 36.64% |
| Total Equity | ₩79.07 Billion | 100.00% |
Hyundai Pharm Competitors by Market Cap
The table below lists competitors of Hyundai Pharm ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Modiv Inc
NYSE:MDV
|
$152.69 Million |
|
Ryvu Therapeutics SA
WAR:RVU
|
$152.71 Million |
|
Merafe
JSE:MRF
|
$152.74 Million |
|
Ecomate Holdings Bhd
KLSE:0239
|
$152.81 Million |
|
Laramide Resources Ltd
AU:LAM
|
$152.52 Million |
|
Euroapi SAS
PA:EAPI
|
$152.50 Million |
|
Duta Intidaya Tbk PT
JK:DAYA
|
$152.47 Million |
|
msg life ag
HM:MSGL
|
$152.38 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Hyundai Pharm's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 84,661,467,620 to 79,074,176,370, a change of -5,587,291,250 (-6.6%).
- Net loss of 574,887,510 reduced equity.
- Dividend payments of 923,125,880 reduced retained earnings.
- Share repurchases of 2,057,830,210 reduced equity.
- Other factors decreased equity by 2,031,447,650.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-574.89 Million | -0.73% |
| Dividends Paid | ₩923.13 Million | -1.17% |
| Share Repurchases | ₩2.06 Billion | -2.6% |
| Other Changes | ₩-2.03 Billion | -2.57% |
| Total Change | ₩- | -6.60% |
Book Value vs Market Value Analysis
This analysis compares Hyundai Pharm's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.85x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 2.07x to 2.85x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-11-30 | ₩4159.65 | ₩8620.00 | x |
| 2018-11-30 | ₩3907.97 | ₩8620.00 | x |
| 2019-11-30 | ₩3244.92 | ₩8620.00 | x |
| 2020-11-30 | ₩3233.36 | ₩8620.00 | x |
| 2021-11-30 | ₩3106.36 | ₩8620.00 | x |
| 2022-11-30 | ₩3143.63 | ₩8620.00 | x |
| 2023-11-30 | ₩3174.38 | ₩8620.00 | x |
| 2024-11-30 | ₩3025.52 | ₩8620.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Hyundai Pharm utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -0.73%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -0.33%
- • Asset Turnover: 1.12x
- • Equity Multiplier: 1.98x
- Recent ROE (-0.73%) is below the historical average (0.79%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2010 | 3.21% | 2.65% | 0.85x | 1.42x | ₩-6.28 Billion |
| 2011 | 0.50% | 0.46% | 0.73x | 1.51x | ₩-9.87 Billion |
| 2012 | -4.89% | -4.74% | 0.68x | 1.51x | ₩-14.77 Billion |
| 2013 | 1.40% | 1.31% | 0.75x | 1.42x | ₩-8.66 Billion |
| 2016 | 1.26% | 1.05% | 0.80x | 1.50x | ₩-8.75 Billion |
| 2017 | 1.49% | 1.12% | 0.84x | 1.58x | ₩-8.35 Billion |
| 2018 | 0.87% | 0.69% | 0.84x | 1.48x | ₩-9.77 Billion |
| 2019 | 1.32% | 0.86% | 0.93x | 1.66x | ₩-7.60 Billion |
| 2020 | 2.43% | 1.64% | 0.84x | 1.75x | ₩-6.83 Billion |
| 2021 | -3.66% | -2.27% | 0.85x | 1.89x | ₩-11.83 Billion |
| 2022 | -0.19% | -0.10% | 0.90x | 2.09x | ₩-8.82 Billion |
| 2023 | 7.23% | 3.39% | 1.17x | 1.83x | ₩-2.34 Billion |
| 2024 | -0.73% | -0.33% | 1.12x | 1.98x | ₩-8.48 Billion |
Industry Comparison
This section compares Hyundai Pharm's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $417,135,058,503
- Average return on equity (ROE) among peers: 2.50%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Hyundai Pharm (004310) | ₩77.99 Billion | 3.21% | 1.09x | $152.68 Million |
| Dongwha Pharm.Co.Ltd (000020) | $296.94 Billion | 15.83% | 0.24x | $113.83 Million |
| Yuhan Corp. (000100) | $756.45 Billion | 11.87% | 0.32x | $4.57 Billion |
| Yuhan Corp Preferred (000105) | $1.61 Trillion | 6.79% | 0.30x | $59.61 Million |
| Yuyu Pharma (000220) | $73.73 Billion | -0.34% | 0.41x | $46.55 Million |
| Yuyu Pharma Inc (000225) | $123.37 Billion | -4.85% | 0.58x | $17.67 Million |
| Yuyu Pharma Inc (000227) | $71.49 Billion | -10.45% | 0.42x | $42.93 Million |
| Ildong Holdings Co Ltd (000230) | $164.95 Billion | -2.25% | 0.61x | $76.14 Million |
| Samil Pharm (000520) | $65.75 Billion | -8.13% | 2.44x | $127.90 Million |
| Donga Socio Holdings (000640) | $746.90 Billion | 2.65% | 0.82x | $427.15 Million |
| Jw Pharmac (001060) | $265.44 Billion | 13.94% | 1.43x | $476.78 Million |
About Hyundai Pharm
Hyundai Pharmaceutical Co., Ltd. manufactures and distributes pharmaceutical products, health food drinks, and medical devices in South Korea and internationally. The company offers a range of ETC and OTC products in various therapeutic areas, including antianginal, antibiotic, antiemetics+antinauseants, antihistamines and antiallergics, antihyperlipidemic, antihypertensive, antiplatelet agent, a… Read more